Amphastar's Q3: Mixed Results, Bright Future

episode

Business News Today | 2 Min News | The Daily News Now! not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

More from Business News Today | 2 Min News | The Daily News Now!

Japanese Capsule Hotels: Budget Solution for London Hybrid Workers 1 min · 20 Dec 2025

Russia's War Economy: Sustainable or Unsustainable? 2 min · 20 Dec 2025

All episodes from Business News Today | 2 Min News | The Daily News Now! →

Report any issue

Source

Recorded10 Nov 2025

Publisherfeeds.acast.com ↗

Handlerec:2198412

Show notes

Amphastar Pharmaceuticals reported mixed Q3 2025 results, with revenue meeting expectations but sales flat compared to last year. However, non-GAAP profit significantly beat estimates by nearly 13%. Key products BAQSIMI and Primatene MIST drove growth, but operating margins were pressured by product mix shifts, price reductions, and competition. Higher costs and legal provisions also impacted profitability. Amphastar plans to expand its proprietary product pipeline, focusing on oncology and ophthalmology, and aims to quadruple US manufacturing capacity by 2026. Despite potential risks, the company is optimistic about future growth and profitability.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.